ClinicalTrials.gov
public full text
Public Domain
Ranibizumab and the Risk of Arterial Thromboembolic Events
The investigators assume that ranibizumab might be dangerous in patients with history of coronary artery disease or cerebrovascular events. The main objective of study is to reveal contraindications for ranibizumab prescription in patients with history of coronary artery disease and cerebrovascular events. Moreover, an association between management with ranibizumab and ATE rate in healthy above 50 years old persons is a concern of great interest as well.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting#979487
- Study of Efficacy of Different Treatment Regimens of Olokizumab#1364407
- A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD#904459
- Detection of Neutralizing Antibodies in Patients Treated With Bevacizumab or Ranibizumab#1246130
- Bangladesh Journal of Pharmacology#18391
Record · ID 1384769
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive